ABL Bio

298380.KQ

31.84 USD

3.85

+13.75%

Overview

Last close

31.84 usd

Market cap

1.78B usd

52 week high

171.55 usd

52 week low

26.37 usd

Target price

202.25 usd

Valuation

P/E

N/A

Forward P/E

N/A

Price/Sales

68.8348

Price/Book Value

11.6241

Enterprise Value

1.41B usd

EV/Revenue

54.8818

EV/EBITDA

-32.1061

Key financials

Revenue TTM

25.68M usd

Gross Profit TTM

25.60M usd

EBITDA TTM

-61.57M usd

Earnings per Share

-1.05 usd

Dividend

N/A usd

Total assets

176.88M usd

Net debt

N/A usd

About

ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company offers ABL301, which is in the phase 1 clinical stage for the treatment of parkinson's disease; ABL503 and ABL111 that is in phase 1 clinical stage for the treatment of solid tumor; and ABL102 for the treatment of solid and blood tumor. It also provides ABL103 for the treatment solid cancers; ABL104 for the treatment of solid tumor; and ABL105, which is in phase 1 clinical stage for the treatment of solid tumor. ABL Bio Inc. was incorporated in 2016 and is based in Seoul, South Korea.